



**DEVONIAN HEALTH GROUP INC.**

**PRESS RELEASE**

*For immediate release*

**Devonian Announces voting results of the Annual General and Special Meeting**

**QUÉBEC, Québec – January 31<sup>st</sup>, 2019** – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation, today announces the voting results of its Annual General and Special Meeting held on January 29, 2019 in Quebec City, Quebec. The number of shares represented in person or by proxy represented 74.01 % of the total issued and outstanding Devonian’s shares.

**Election of Directors**

The seven (7) candidates nominated for election to the Devonian’s Board of Directors and listed in the Corporation’s Management Information Circular, dated December 21<sup>st</sup>, 2018, were elected by a majority of the votes cast by shareholders present in person or represented by proxy at the meeting as follows:

<b>Name</b>	<b>Votes For (%)</b>	<b>Votes Withheld (%)</b>
Jacques Bernier	100	
André P. Boulet	100	
Borys Chabursky	100	
Sybil Dahan	100	
Louis Flamand	100	
Terry L. Fretz	100	
Tarique Sayed	100	



### **Appointment of Auditors**

Devonian also announces today that its shareholders have approved the re-appointment of Mallette LLP as the Auditor of the Corporation to hold office until the next annual meeting of shareholders.

### **Ratification and Confirmation of the Corporate's Stock Option Plan**

Devonian also announced today that 99.89% of its shareholders have ratified and confirmed the Corporate's Stock Option Plan.

### **About Devonian**

Devonian is a clinical stage pharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs. This focus is supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway versus those for traditional prescription medicines. Devonian is founded on a broad-based platform that spans more than fifteen years of research. Devonian's proprietary process of extraction, purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic process in plants and algae is known as: The Supra Molecular Complex Extraction and Stabilisation Technology (SUPREX™). Thykamine™ is the first product derived from this platform. The potent anti-inflammatory and anti-oxidative active properties of Thykamine™ have been demonstrated in several pre-clinical studies as well as in a clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now moving into large phase II clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business, Devonian is also involved in the development of high value derma-cosmeceutical products as part of a secondary strategy to generate short-term revenues and optimize manufacturing efficiency.

For more information, visit [www.groupe-devonian.com](http://www.groupe-devonian.com).



## **Forward Looking Statements**

This press release contains forward-looking statements about Devonian's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian's transformation into a leading healthcare company, the creation of a compelling financial and operational platform for future growth, the expectation that Altius maintains its existing operations as a new division of Devonian, the receipt of TSXV approval to proceed with the acquisition Devonian's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian's prospectus dated April 21<sup>st</sup>, 2017 under the heading "Risk Factors" related to Devonian's business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

Contact: Dr. André P. Boulet, PhD  
President and Chief Executive Officer  
Devonian Health Group Inc.  
Telephone: (514) 248-7509  
e-mail: [apboulet@groupe-devonian.com](mailto:apboulet@groupe-devonian.com)